



EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary

European Association for the Study of the Liver¹ · European Association for the Study of Diabetes² · European Association for the Study of Obesity³ · Clinical Practice Guideline Panel

© by the European Association for the Study of Diabetes 2024

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the presence of one or more cardiometabolic risk factor(s) and the absence of harmful alcohol intake. The spectrum of MASLD includes steatosis, metabolic dysfunction-associated steatohepatitis (MASH, previously NASH), fibrosis, cirrhosis and MASH-related hepatocellular carcinoma (HCC). This joint EASL–EASD–EASO guideline provides an update on definitions, prevention, screening, diagnosis and treatment for MASLD. Case-finding strategies for MASLD with liver fibrosis, using non-invasive tests, should be applied in individuals with cardiometabolic risk factors, abnormal liver enzymes and/or radiological signs of hepatic steatosis, particularly in the presence of type 2 diabetes or obesity with additional metabolic risk factor(s). A stepwise approach using blood-based scores (such as the fibrosis-4 index [FIB-4]) and, sequentially, imaging techniques (such as transient elastography) is suitable to rule-out/in advanced fibrosis, which is predictive of liver-related outcomes. In adults with MASLD, lifestyle modification—including weight loss, dietary changes, physical exercise and discouraging alcohol consumption—as well as optimal management of comorbidities—including use of incretin-based therapies (e.g. semaglutide, tirzepatide) for type 2 diabetes or obesity, if indicated—is advised. Bariatric surgery is also an option in individuals with MASLD and obesity. If locally approved and dependent on the label, adults with non-cirrhotic MASH and significant liver fibrosis (stage ≥ 2) should be considered for a MASH-targeted treatment with resmetirom, which demonstrated histological effectiveness on steatohepatitis and fibrosis with an acceptable safety and tolerability profile. No MASH-targeted pharmacotherapy can currently be recommended for the cirrhotic stage. Management of MASH-related cirrhosis includes adaptations of metabolic drugs, nutritional counselling, surveillance for portal hypertension and HCC, as well as liver transplantation in decompensated cirrhosis.

Keywords Diabetes · Glucagon-like peptide · Hepatocellular carcinoma · Liver fibrosis · MASH · MASLD · NAFLD · NASH · Non-invasive tests · Resmetirom

The full guidelines were developed by the European Association for the Study of the Liver (EASL), the European Association for the Study of Diabetes (EASD) and the European Association for the Study of Obesity (EASO), and jointly published in the *Journal of Hepatology* (DOI <https://doi.org/10.1016/j.jhep.2024.04.031>) and *Obesity Facts* (DOI <https://doi.org/10.1159/000539371>). This is an executive summary of the guidelines produced with permission. Either citation can be used when citing the full version of the guidelines or the executive summary.

✉ European Association for the Study of Diabetes
info@easd.org

¹ The EASL Building – Home of Hepatology, 7 rue Daubin, CH 1203 Geneva, Switzerland

Abbreviations

ALD	Alcohol-related liver disease
ALT	Alanine aminotransferase
CPG	Clinical Practice Guidelines
CSPH	Clinically significant portal hypertension
EASD	European Association for the Study of Diabetes
EASL	European Association for the Study of the Liver

² European Association for the Study of Diabetes e.V., Rheindorfer Weg 3, 40591 Düsseldorf, Germany

³ EASO Brussels Office, The Library, 10 Square Ambiorix, 1000 Brussels, Belgium

EASO	European Association for the Study of Obesity
ELF	Enhanced liver fibrosis
FIB-4	Fibrosis-4 index
GLP1RA	Glucagon-like peptide 1 receptor agonists
HCC	Hepatocellular carcinoma
LoE	Level of evidence
LSM	Liver stiffness measurement
MASH	Metabolic dysfunction-associated steatohepatitis
MASLD	Metabolic dysfunction-associated steatotic liver disease
MetALD	Metabolic dysfunction-associated steatotic liver disease with moderate (increased) alcohol intake
NAFLD	Non-alcoholic fatty liver disease
SGLT2	Sodium–glucose cotransporter-2
SLD	Steatotic liver disease
VCTE	Vibration-controlled transient elastography

Introduction

Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common chronic liver disease, and its prevalence will likely continue to rise. The presence of MASLD is tightly linked to type 2 diabetes, obesity and other cardiometabolic risk factors. MASLD is associated with an increased risk of cardiovascular events, chronic kidney disease, hepatic and extrahepatic malignancies, and liver-related outcomes, including liver failure and hepatocellular carcinoma (HCC). Therefore, the high socio-economic burden of MASLD poses a global health challenge that needs to be addressed by medical societies and policymakers [1].

MASLD is defined as the presence of excess triglyceride storage in the liver in the presence of at least one cardiometabolic risk factor. The term MASLD comprises different conditions, including isolated liver steatosis (metabolic dysfunction-associated steatotic liver, MASL), metabolic dysfunction-associated steatohepatitis (MASH), as well as fibrosis and cirrhosis. MASH is characterised by histological features of hepatocellular ballooning and lobular inflammation. MASLD replaces the old term non-alcoholic fatty liver disease (NAFLD) and is embedded in the new consensus definition of steatotic liver disease (SLD). Besides MASLD, SLD also includes MASLD with moderate (increased) alcohol intake (MetALD), alcohol-related liver disease (ALD), specific aetiologies of SLD (e.g. drug-induced, monogenic diseases) and cryptogenic SLD (Fig. 1) [2].

The current Clinical Practice Guidelines (CPGs) for the diagnosis, treatment and follow-up of individuals with MASLD have been generated as a joint effort by the European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). They update the multi-society NAFLD CPG released in 2016 [3].

Intensified research efforts in recent years have significantly expanded our understanding of the pathophysiology and natural course of the disease. This has culminated in improved diagnostic tools and novel therapeutic options, which is reflected in the expanded scope of the current CPG. The availability of improved treatment options underlines the need to identify at-risk individuals with MASLD early, as we now possess the tools to positively influence the course of the disease, which is expected to prevent relevant clinical events.

These CPGs are targeted at healthcare providers involved in the care of individuals with (or at risk of) MASLD. They provide a framework for the early identification of affected individuals, risk stratification and therapeutic management including non-pharmacological and pharmacological treatment. Furthermore, they provide guidance on the management of end-stage MASLD and MASLD in the setting of advanced liver disease and liver transplantation.

The purpose of this document is to assist physicians, affected and at-risk individuals, healthcare providers and health-policymakers from Europe and worldwide in the decision-making process, by providing evidence-based data, which also takes into consideration the burden of clinical management for the healthcare system. The recommendations are intended to guide clinical practice in circumstances where all possible resources and therapies are available. Thus, users should adapt the recommendations to their local regulations, availability of resources, infrastructure and cost–benefit strategies.

Preamble

The nomenclature of SLD and definition of MASLD were established in June 2023, following an international, multi-society guided Delphi process [2]. The diagnosis of MASLD requires the presence of at least one cardiometabolic risk factor in an individual with documented steatosis. This has raised concerns as to whether evidence generated under the NAFLD definition would still apply to individuals with MASLD. Several re-examinations from existing cohort studies support that NAFLD-related findings can be fully extrapolated to individuals with MASLD. As an example, analyses of a large tertiary care NAFLD cohort and the population-based Nutrition Examination Survey (NHANESIII) data found a




Fig. 1 Flow chart for SLD and its sub-categories [2]. SLD, diagnosed histologically or by imaging, has many potential aetiologies. MASLD is defined as the presence of hepatic steatosis in conjunction with (at least) one cardiometabolic risk factor and no other discernible cause.

nearly complete overlap between NAFLD and MASLD populations, with 99.8% accordance in the NAFLD cohort, while only 5.3% of individuals with NAFLD in the NHANESIII database did not fulfil the MASLD criteria [4]. In addition, clinical characteristics were almost identical, and non-invasive tests showed equal accuracy and cut-offs for both definitions [4]. Finally, long-term follow-up showed similar mortality rates, with slightly higher mortality in MASLD compared to NAFLD [4]. Therefore, we have transferred the evidence on NAFLD to the MASLD population and use the term MASLD interchangeably. Notably, MetALD represents a distinct entity to which our recommendations and statements generated with the ‘pure’ NAFLD definition may not apply.

Methods

The levels of evidence (LoE) for all statements and recommendations were developed by applying the Oxford Centre for Evidence-based Medicine system (electronic supplementary material [ESM] Table 1) [5]. The strength of recommendations reflects the quality (grade) of underlying evidence (ESM Table 2). In cases where the committee determined guidance to be necessary despite a lack of available supporting literature, a recommendation was developed based on expert opinion and consensus.

The quantity of alcohol intake, the drinking pattern, and the type of alcohol consumed should be assessed in all individuals with SLD using detailed medical history, psychometric instruments and/or validated biomarkers

The draft statements and recommendations of the CPG panel were sent to an international 46-member Delphi panel, including clinicians, patient representatives and other stakeholders competent in the field of MASLD, for consensus agreement, where $\geq 95\%$ agreement was classified as strong consensus and 75–95% were classified as consensus. Neutral votes were not counted when calculating the consensus.

Definition, prevalence and natural course

Is the presence of steatotic liver in the general population an important factor in identifying individuals at risk for liver-related outcomes, independent of the presence of other hepatotoxic factors?

Recommendations

- The incidental finding of steatosis should prompt assessment of the potential aetiology of SLD, alongside tests for the presence of advanced fibrosis, as this could determine the risk of liver-related and/or cardiovascular outcomes and appropriate care (**LoE 3, strong recommendation, strong consensus**).
- MASLD, ALD and MetALD are the most common causes of SLD, but other causes such as drug-induced

liver disease and monogenic SLD should be considered, depending on the context (**LoE 3, strong recommendation, strong consensus**).

- General population-based screening for SLD is not advised (**LoE 3, strong recommendation, strong consensus**).

Statement

- While the presence of steatotic liver in the general population is not independently associated with liver-related outcomes, the stage of liver fibrosis and persistently elevated liver enzymes are associated with liver-related outcomes (**LoE 3, strong consensus**).

A proposal for the simplified diagnostic work-up of a case of SLD is outlined in Fig. 1. Cardiometabolic risk factors and their cut-offs for the definition of MASLD are summarised in ESM Table 3. Other causes of SLD (ESM Table 4) should be considered when all other factors have been excluded (Fig. 1).

Which risk factors and comorbidities have the greatest impact on the natural history of the hepatic disease including HCC in MASLD?

Statements

- Type 2 diabetes and obesity (particularly abdominal obesity) are the metabolic diseases with the strongest impact on the natural history of MASLD, including progression to MASLD/MASH-related advanced fibrosis, cirrhosis and hepatocellular carcinoma (**LoE 2, strong consensus**).
- Men aged >50 years, postmenopausal women and individuals with multiple cardiometabolic risk factors are at increased risk of progressive fibrosis and the development of cirrhosis and its complications (**LoE 2, strong consensus**).

Does any alcohol consumption in adults with non-cirrhotic or cirrhotic MASLD have an adverse effect on the natural course of liver disease?

Statements

- Accumulating evidence shows that alcohol consumption and metabolic risk factors have modifying effects on the onset and progression of chronic liver disease, which are independent and can be synergistic (**LoE 2, strong consensus**).
- The presumed beneficial health effects of moderate alcohol consumption are inconsistent across studies, and

emerging evidence does not support a protective effect of light to moderate amounts of alcohol, particularly in individuals with cardiometabolic risk factors (**LoE 3, strong consensus**).

Recommendations

- The amount, pattern and history of alcohol intake should be documented in all individuals with SLD (**LoE 3, strong recommendation, strong consensus**).
- Alcohol intake may be qualitatively and quantitatively assessed by validated instruments and/or specific biomarkers in individuals with SLD (ESM Table 5) (**LoE 3, open recommendation, strong consensus**).
- Individuals with SLD, particularly those with moderate or high alcohol intake, should be discouraged from consuming alcohol (**LoE 3, strong recommendation, consensus**).
- All alcohol consumption should be stopped completely and permanently in individuals with advanced fibrosis or cirrhosis (**LoE 3, strong recommendation, strong consensus**).

Prevention

In the general population or high-risk groups, can non-pharmacological measures be recommended to prevent the development of MASLD and its adverse complications, including HCC?

Recommendation

- In the general population, non-pharmacological measures should be recommended to prevent the development of MASLD and its complications, including hepatocellular carcinoma, and preventive measures should be reinforced in high-risk groups (**LoE 3, strong recommendation, strong consensus**).

Screening, case-finding, diagnosis and monitoring

Should a policy of screening for MASLD at risk of fibrotic disease (or fibrosis progression) in primary care or at the non-hepatology specialist level be implemented in the general population or only in individuals with cardiometabolic risk factors?

Which at-risk individuals should undergo case-finding for MASLD at risk of fibrotic disease (or fibrosis progression) in the primary care (or other specialty) setting to reduce hepatic complications of MASLD?

Recommendations

- Healthcare providers may consider case-finding strategies for MASLD with liver fibrosis in individuals with cardiometabolic risk factors (ESM Table 3), abnormal liver enzymes and/or radiological signs of hepatic steatosis (**LoE 3, weak recommendation, consensus**).
- Healthcare providers should look for MASLD with liver fibrosis either in individuals with (1) type 2 diabetes; (2) abdominal obesity and ≥ 1 additional metabolic risk factor(s) (ESM Table 3); or (3) abnormal liver function tests (**LoE 3, strong recommendation, consensus**).

Statement

- Early diagnosis of fibrosis and subsequent appropriate management can potentially prevent progression to cirrhosis and its complications and may justify screening in these populations at risk (**LoE 3, strong consensus**).

In the adult population with MASLD, are selected non-invasive scores and imaging modalities more useful than liver enzyme testing for the detection of MASLD with fibrosis?

In adults with MASLD or at-risk individuals, are clinical care pathways based on the sequential application of non-invasive scores and imaging cost-effective for the identification and management of individuals with MASLD at risk of fibrotic disease (or of fibrosis progression) compared to referral based on physician's discretion?

Recommendations

- In adults with MASLD, non-invasive scores based on combinations of blood tests or combinations of blood tests with imaging techniques measuring mechanical properties and/or hepatic fat content should be used for the detection of fibrosis since their diagnostic accuracy is higher than standard liver enzyme testing (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) (**LoE 2, strong recommendation, strong consensus**).
- In adults with MASLD, a multi-step approach is recommended (detailed in Fig. 2): first, an established non-patented blood-based score, such as the fibrosis-4 index (FIB-4), should be used. Thereafter, established imaging techniques, such as liver elastography, are recommended as a second step to further clarify the fibrosis stage if fibrosis is still suspected or in high-risk groups (**LoE 2, strong recommendation, strong consensus**).
- Tests of specific collagen-related blood constituents (e.g. enhanced liver fibrosis [ELF]) may serve as an alternative to imaging to identify advanced liver fibrosis (**LoE 2, open recommendation, consensus**).

- Clinical care pathways may be adopted based on the sequential application of non-invasive scores and imaging tests in adults with MASLD or at-risk individuals, recognising that most adults with MASLD are seen in non-hepatology settings (**LoE 2, weak recommendation, strong consensus**).

In adults with MASLD, should non-invasive scores, circulating biomarkers, liver stiffness measurement and imaging methods replace liver biopsy for the diagnosis of MASH and/or advanced fibrosis?

Recommendation


- Blood biomarker-derived scores and elastography should be used to exclude advanced fibrosis, while elastography is better suited to predict advanced fibrosis (**LoE 2, strong recommendation, consensus**).

Statements

- None of these non-invasive methods can assess relevant microscopic features of MASLD such as ballooning or lobular inflammation (**LoE 2, strong consensus**).
- Some blood biomarker-based scores may help to identify individuals with MASH at risk of disease progression (**LoE 3, consensus**).
- Blood biomarker-derived scores and elastography can help in risk stratification for clinical outcomes, as observational studies have identified thresholds related to liver-related outcomes and mortality (**LoE 3, strong consensus**).
- In most cases, liver biopsy is not required for clinical management of individuals with MASLD; however, liver biopsy is still required for the definite diagnosis of steatohepatitis and can help to rule out alternative causes of liver disease (**LoE 1, strong consensus**).

Non-invasively obtained blood-based biomarkers (such as FIB-4 and ELF) and measurements of liver stiffness (vibration-controlled transient elastography [VCTE] or magnetic resonance elastography [MRE]) are suitable for reliably detecting advanced fibrosis with positive and negative predictive values strongly dependent on the chosen cut-off values and the prevalence of fibrosis of different stages in the studied population (Table 1).

In adults with MASLD, should non-invasive scores, circulating biomarkers, liver stiffness measurement and imaging techniques be used as a surrogate for liver biopsy to monitor progression of MASH and predict liver-related outcomes?



* FIB-4 thresholds valid for age ≤65 years (for age >65 years: lower FIB-4 cut-off is 2.0)

** e.g. lifestyle intervention, treatment of comorbidities (e.g. GLP1RA), bariatric procedures

*** e.g. MRE, SWE, ELF, with adapted thresholds

Ⓐ and Ⓑ are options, depending on medical history, clinical context and local resources

Fig. 2 Proposed strategy for non-invasive assessment of the risk for advanced fibrosis and liver-related outcomes in individuals with metabolic risk factors or signs of SLD. Individuals with (1) type 2 diabetes or (2) abdominal obesity and ≥ 1 additional cardiometabolic risk factor(s) or (3) persistently elevated liver enzymes should undergo a multi-step diagnostic process, as indicated in the figure, to identify

individuals with MASLD and advanced fibrosis. The algorithm can also be applied in case of incident finding of steatosis. This strategy is intended to identify individuals at risk of developing liver-related outcomes. MRE, magnetic resonance elastography; SWE, shear wave elastography

Recommendations

- In adults with MASLD, sequential assessment with non-invasive tools may assist in ruling out fibrosis progression (**LoE 3, weak recommendation, strong consensus**).
- In adults with MASLD, non-invasive tools (Table 1) can help predict the risk of overall and liver-related events and mortality (**LoE 2, weak recommendation, strong consensus**).

Evidence for the ability of non-invasive tests to predict outcomes in MASLD as well as suggested thresholds for diagnostic purposes are summarised in Table 1.

In adults with MASLD, does genetic testing (alone or in combination) provide an additional advantage over other non-invasive scores and imaging in predicting risk of liver disease development, severity, progression and liver-related outcomes, or response to specific therapeutic approaches?

Recommendations

- Clinicians in specialised centres may consider assessing the genetic risk profile (e.g. *PNPLA3* p.I148M variant and/or polygenic risk scores) to personalise risk stratification, but this concept should be evaluated in larger prospective studies (**LoE 3, open recommendation, consensus**).
- Genetic risk variants can be evaluated in clinical studies for stratification of disease risk progression and sub-phenotyping of MASLD (**LoE 3, open recommendation, strong consensus**).
- Clinicians can consider referring individuals with a strong family history of severe disease in first degree relatives or early presentation with a severe phenotype, especially in the absence of metabolic triggers (and/or e.g. in individuals with normal body weight), for the evaluation of coexisting, treatable, genetic causes of liver disease by next-generation sequencing approaches (**LoE 4, open recommendation, consensus**).

Table 1 Targets of different non-invasive techniques (selection) and suggested thresholds for ruling out/in certain features of MASLD

Non-invasive test	Biological processes reflected	Rule-out cut-off	Rule-in cut-off	Prediction of liver-related outcomes
Primary target: hepatic steatosis				
US scan—standard VCTE: CAP [8]	Lipid content	N/A	N/A	+
	Lipid content	S1: 248 dB/m S2: 268 dB/m S3: 280 dB/m		?
MRI—MRI-PDFF	Lipid content	S1: 5% S2: 11–18% S3: 16–23%		+
Primary target: hepatic fibrosis				
AST/ALT ratio	Stress to hepatocytes	F3: 0.8	F3: 1.0	+
FIB-4	Stress to hepatocytes, hypersplenism	F2: 0.66–0.89 F3: 1.3	F2: 2.67 F3: 2.67	++
APRI	Stress to hepatocytes, hypersplenism	F3: 0.5	F3: 1.5	++
NFS	Stress to hepatocytes, hypersplenism, metabolic burden	F3: –1.455	F3: 0.676	++
ELF	Collagen metabolism	F3: 7.7	F3: 9.8	+++
ADAPT	Collagen metabolism, hypersplenism, metabolic burden	F3: 4.46	F3: 7.15	?
VCTE: LSM (liver stiffness)	Fibrosis, extracellular volume fraction	F3: 8 kPa	F3: 12 kPa	+++
US—2D-SWE	Fibrosis, extracellular volume fraction	F3: 8 kPa	F3: 10.5 kPa	+++
MRI—MRE	Fibrosis, extracellular volume fraction	F2: 3.14 kPa F3: 3.53 kPa F4: 4.45 kPa		+++
MEFIB	Stress to hepatocytes, fibrosis, hypersplenism	F2: MRE <3.3 kPa and FIB-4 <1.6	F2: MRE ≥3.3 kPa and FIB-4 ≥1.6	+++
Primary target: ‘at-risk MASH’				
FAST	Stress to hepatocytes, fibrosis, lipid content	0.35	0.67	++
MAST	Stress to hepatocytes, fibrosis, lipid content	0.165	0.242	++
Corrected T1	Extracellular volume fraction, (fibrosis)	825 ms	875 ms	++
NIS2+	Stress to hepatocytes, fibrosis, extracellular matrix remodelling	0.46	0.68	?

The predictive value of the procedure for liver-related outcomes (e.g. cirrhosis complications, HCC, liver-related death) is qualitatively depicted (+ low, ++ moderate, +++ high, ? unknown)

Merged cells represent non-invasive techniques with single cut-offs

ADAPT, age, presence of diabetes, PRO-C3, and platelet count; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; CAP, controlled attenuation parameter; F1–F4, fibrosis stage (F2: moderate fibrosis, F3: severe fibrosis, F4: cirrhosis); FAST, FibroScan-AST; MAST, MRI-AST; MEFIB, MRE combined with FIB-4; MRE, magnetic resonance elastography; N/A, not applicable; NFS, NAFLD fibrosis score; PDFF, proton density fat fraction; S1–S3, stage of steatosis (S1: mild [<10% hepatocytes], S2: moderate [10%–30% hepatocytes], S3: severe [>30% hepatocytes] steatosis); SWE, shear wave elastography; US, ultrasound

Is the assessment of metabolic abnormalities (e.g. insulin sensitivity/resistance) useful for risk stratification or management of adults with MASLD?

In adults with MASLD, should diagnostic procedures be performed for associated comorbidities (e.g. cardiovascular diseases, diabetes, dyslipidaemia or obesity)?

Recommendations

- Clinicians should assess associated comorbidities (e.g. type 2 diabetes, dyslipidaemia, hypertension, kidney dis-

ease, sleep apnoea, polycystic ovary syndrome) and cardiovascular risk in adults with MASLD (**LoE 2, strong recommendation, strong consensus**).

- At initial diagnosis of MASLD and at regular follow-up intervals, laboratory tests and physical examinations for related comorbidities are recommended (Table 2) (**LoE 2, strong recommendation, strong consensus**).
- Adults with MASLD should be encouraged to participate in extrahepatic cancer screening according to current guidelines, based on their exposure to obesity and type

2 diabetes as risk factors for extrahepatic malignancies (**LoE 3, strong recommendation, strong consensus**).

- Assessment of insulin resistance (e.g. using the homeostasis model assessment of insulin resistance [HOMA-IR] or estimates derived from the oral glucose tolerance test) may be considered to clarify metabolic dysfunction in adults with (suspected) MASLD and without an established diagnosis of type 2 diabetes (**LoE 3, weak recommendation, consensus**).

In adults with non-cirrhotic MASLD or MASH, is surveillance indicated for early detection of HCC?

Recommendations

- In adults with non-cirrhotic MASLD or MASH in the absence of severe fibrosis (i.e. those with fibrosis stage <F3) assessed by non-invasive markers or liver biopsy, surveillance for early detection of hepatocellular carcinoma is currently not recommended (**LoE 3, weak recommendation, consensus**).
- In adults with non-cirrhotic MASLD or MASH in the presence of severe fibrosis (F3) assessed by non-invasive markers or liver biopsy, surveillance may be considered based on an individual risk assessment (**LoE 4, weak recommendation, strong consensus**).

Should HCC monitoring programmes be implemented in all adults with MASH-related cirrhosis, or should they be implemented based on risk stratification?

Recommendations

- According to current guidelines, hepatocellular carcinoma monitoring programmes should be applied to individuals with MASLD-related cirrhosis (**LoE 3, strong recommendation, strong consensus**).
- Risk stratification can help in optimising strategies for monitoring individuals at higher risk of hepatocellular carcinoma (ESM Tables 6 and 7) (**LoE 4, weak recommendation, strong consensus**).
- As ultrasound-based surveillance has a low sensitivity for detection of hepatocellular carcinoma at an early-stage, particularly in adults with MASLD-related cirrhosis and obesity, alpha-fetoprotein (AFP) measurement can be combined with ultrasound in individuals at high risk (**LoE 3, open recommendation, consensus**).
- Cross-sectional imaging by MRI may be undertaken in selected adults at high risk with persistent poor visualisation at ultrasound, particularly in individuals with

dysplastic or regenerative nodules (**LoE 3, open recommendation, strong consensus**).

Algorithms combining demographic and clinical variables with blood-based biomarkers to assess the risk of HCC development are summarised in ESM Table 7. However, none of these calculators have been validated in Phase III/IV studies.

Treatment of MASLD: general considerations

In adults with MASLD, which of the following—reduction of steatosis, resolution of MASH, improvement of fibrosis, stabilisation of fibrosis, prevention of progression to cirrhosis—is the most relevant therapeutic target for improving liver-related outcomes?

Statements

- In adults with MASLD and advanced fibrosis or cirrhosis, regression of fibrosis has been associated with a reduced risk of liver-related outcomes (**LoE 2, strong consensus**).
- Improvement in disease activity and resolution of steatohepatitis have been associated with regression of fibrosis (**LoE 2, strong consensus**).
- Reduction of steatosis has been associated with histological improvements (particularly necro-inflammation) in some pharmacological intervention studies (**LoE 2, strong consensus**).
- Since improved mortality has not been demonstrated for any of these treatment-induced histological changes, further long-term follow-up studies are needed to demonstrate that halting disease progression and/or reduction of steatosis, resolution of steatohepatitis or regression of fibrosis translate into a reduced risk of clinical outcomes (**LoE 3, strong consensus**).

In adults with MASLD, should non-invasive scores, serum markers, liver stiffness measurements and imaging be used as a substitute for liver biopsy for monitoring therapeutic responses?

Statements

- Non-invasive tests have been linked with histologically assessed treatment response, but the most appropriate non-invasive test may depend on the type of intervention and patient-related factors (**LoE 2, strong consensus**).

Table 2 Diagnostic procedures to identify relevant comorbidities of MASLD

Comorbidity	Assessment/parameter
Obesity	BMI Waist circumference Waist to height ratio Further investigations ^a : Body composition analysis (if available) TSH and free thyroxine (if suspicion of hypothyroidism)
Type 2 diabetes or insulin resistance	Fasting plasma glucose HbA _{1c} Oral glucose tolerance test, 2 h post-load glucose Fasting plasma insulin and/or C-peptide HOMA-IR Further investigations ^a : Insulin resistance indices from oral glucose tolerance test or mixed meal tests
Dyslipidaemia	Fasting plasma triglycerides Fasting plasma total, LDL- and HDL-cholesterol Once in a lifetime: measurement of lipoprotein (a) Further investigations ^a : Non-esterified fatty acids Apolipoprotein B
Kidney disease	Creatinine in plasma and urine Albumin in serum and urine Estimated glomerular filtration rate (eGFR)
Cardiovascular disease	Fasting plasma uric acid Serum high-sensitivity C-reactive protein (hsCRP) Serum ferritin Systolic and diastolic blood pressure Further investigations ^a : 24 h ambulatory blood pressure monitoring Echocardiography for heart failure Serum NT-ProBNP Transferrin saturation
Atherosclerosis	Complete blood count; Platelets Elevated lipoprotein (a) is an independent causal risk factor for atherosclerotic cardiovascular disease Further investigations ^a : Fibrinogen Homocysteine Von Willebrand factor antigen Carotid artery intima media thickness EchoDoppler plaque instability Coronary artery calcification
Obstructive sleep apnoea	Neck circumference Epworth score Further investigations ^a : Sleep studies Overnight pulse oximetry Polisomnography CPAP trial
PCOS	Sex hormones: LH, FSH, testosterone, SHBG Ovarian ultrasound

^aAccording to clinical evaluation and a priori probability

CPAP, continuous positive airway pressure; FSH, follicle-stimulating hormone; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance; LDL, low-density lipoprotein; LH, luteinising hormone; NT-ProBNP, N-terminal pro-B-type natriuretic peptide; PCOS, polycystic ovary syndrome; SHBG, sex hormone binding globulin; TSH, thyroid-stimulating hormone

- Longitudinal changes in non-invasive test results have been correlated with changes in the risk of adverse outcomes on a cohort or population level (**LoE 3, consensus**).
- In the setting of randomised controlled trials, and depending on the mode of intervention, changes of non-invasive markers (e.g. MRI-estimated proton density fat fraction [MRI-PDFF] relative reduction by $\geq 30\%$, ALT reduction by ≥ 17 U/l) have been associated with resolution of steatohepatitis (**LoE 2, strong consensus**).
- Liver biopsy is not suited for monitoring disease evolution or response to therapy in routine clinical practice due to its invasiveness and procedure-related limitations (**LoE 5, strong consensus**).

Recommendations

- At the individual level, non-invasive tests may be repeatedly used to assess fibrosis progression in a tailored fashion but may provide limited information about treatment response (**LoE 5, weak recommendation, strong consensus**).
- In individual cases and in clinical trials, liver biopsy can be used to monitor disease progression or response to treatment (**LoE 1, open recommendation, strong consensus**).

In adults with MASLD, can the management of liver disease and extrahepatic comorbidities within multidisciplinary teams involving hepatologists and other specialists improve clinical outcomes?

Recommendation

- Given the multidirectional connections between MASLD and cardiometabolic comorbidities, a multidisciplinary approach is recommended to ensure all components are appropriately targeted to improve both liver-related and extrahepatic outcomes (**LoE 3, strong recommendation, strong consensus**).

Treatment of MASLD: non-pharmacological therapy

In adults with MASLD, what is the efficacy of dietary and behavioural therapy-induced weight loss on histologically/non-invasively assessed liver damage/fibrosis and liver-related outcomes compared with no intervention?

Recommendations

- In adults with MASLD, dietary and behavioural therapy-induced weight loss should be recommended to improve liver injury, as assessed histologically or

non-invasively (**LoE 1, strong recommendation, strong consensus**).

- In adults with MASLD and overweight, dietary and behavioural therapy-induced weight loss should aim at a sustained reduction of $\geq 5\%$ to reduce liver fat, 7–10% to improve liver inflammation and $\geq 10\%$ to improve fibrosis (**LoE 2, strong recommendation, strong consensus**).

Statement

- Further follow-up studies are needed to determine the long-term effectiveness of dietary and behavioural therapy-induced weight loss (including its magnitude) on clinical liver-related outcomes and liver-related mortality (**LoE 3, strong consensus**).

Figure 3 gives an overview of the lifestyle management for individuals with MASLD.

In adults with MASLD, is changing diet quality effective in reducing histologically/non-invasively assessed liver damage/fibrosis and liver-related outcomes compared with no intervention?

Recommendation

- In adults with MASLD, improving diet quality (similar to the Mediterranean dietary pattern), limiting the consumption of ultra-processed food (rich in sugars and saturated fat) and avoiding sugar-sweetened beverages should be recommended to improve histologically or non-invasively assessed liver injury (**LoE 2, strong recommendation, strong consensus**).

Statement

- There is little evidence that improving diet quality beneficially impacts clinical liver-related outcomes (**LoE 3, consensus**).

In adults with MASLD, are physical activity and exercise effective at reducing histologically/non-invasively assessed liver damage/fibrosis and liver-related outcomes compared with no intervention?

Recommendation

- In adults with MASLD, physical activity and exercise should be recommended to reduce steatosis, tailored to the individual's preference and ability (preferably >150 min/week of moderate- or 75 min/week of vigorous-intensity physical activity) (**LoE 1, strong recommendation, strong consensus**).




Fig. 3 Lifestyle management algorithm for MASLD. Behavioural therapy includes: self-monitoring, clinicians providing affected individuals with self-efficacy and motivation, setting realistic negotiable goals and overcoming barriers. Examples of unprocessed/minimally processed foods: vegetables, fruits (not juice), low-fat dairy, nuts, olive oil, legumes, unprocessed fish and poultry. Overweight/obesity:

Overweight: BMI of 25–29.9 kg/m² (non-Asian) or 23–24.9 (Asian), Obesity: ≥30 kg/m² (non-Asian) ≥25 kg/m² (Asian). Class II obesity: BMI ≥35 kg/m² (non-Asian) or BMI ≥30 kg/m² (Asian). Normal weight: BMI <25 kg/m² (non-Asian) or <23 kg/m² (Asian). T2D, type 2 diabetes

Statement

- In comparison to the well-documented cardiometabolic benefits, there is less robust evidence for benefits of physical activity and exercise on histological outcomes, non-invasively assessed liver damage/fibrosis and liver-related clinical outcomes (**LoE 5, strong consensus**).

In adults with MASLD who are normal weight, are diet and exercise interventions effective in reducing histologically/non-invasively assessed liver damage/fibrosis and liver-related outcomes in comparison with no intervention?

Recommendation

- In normal-weight adults with MASLD, diet and exercise interventions should be recommended to reduce liver fat (**LoE 3, strong recommendation, strong consensus**).

Statement

- In normal-weight adults with MASLD there is currently no evidence regarding the beneficial effect of diet and/

or exercise on liver histology, fibrosis and liver-related clinical outcomes (**LoE 5, consensus**).

In adults with MASLD, are nutraceuticals (food supplements, herbal products, gut microbiota-modifying agents) effective to reduce histologically/non-invasively assessed liver damage/fibrosis and liver-related outcomes compared with no intervention?

Recommendation

- In adults with MASLD, nutraceuticals cannot be recommended since there is insufficient evidence of their effectiveness in reducing histologically/non-invasively assessed liver damage/fibrosis and liver-related outcomes in MASLD, nor of their safety (**LoE 2, open recommendation, strong consensus**).

Statement

- In adults with MASLD, coffee consumption has been associated with improvements in liver damage and reduced liver-related clinical outcomes in observational studies (**LoE 4, strong consensus**).

Treatment of MASLD: pharmacological therapy

In adults with MASH, is there sufficient evidence to recommend prescription of existing non-glucose-lowering drugs to reduce histologically/non-invasively assessed liver damage/fibrosis and liver-related outcomes compared to no pharmacological intervention?

Recommendations

- If approved locally and dependent on the label, adults with non-cirrhotic MASH with significant liver fibrosis (stage ≥ 2) should be considered for treatment with resmetirom as a MASH-targeted therapy, as this treatment demonstrated histological efficacy on steatohepatitis and fibrosis in a large Phase III registrational trial with an acceptable safety and tolerability profile (**LoE 2, strong recommendation, consensus**).
- Treatment with resmetirom, if approved locally, may be considered for individuals with MASLD who are non-cirrhotic and with documentation of either: (1) advanced fibrosis; (2) at-risk steatohepatitis with significant fibrosis (by liver biopsy, when available, or by non-invasive panels validated for that purpose); or (3) risk of adverse liver-related outcomes (e.g. by elastography- or biomarker-defined thresholds) (**LoE 3, open recommendation, consensus**).
- No MASH-targeted pharmacotherapy can currently be recommended for adults with MASH at the cirrhotic stage (**LoE 5, weak recommendation, strong consensus**).
- Given the lack of robust demonstration of histological efficacy on steatohepatitis and liver fibrosis derived from large Phase III trials and potential long-term risks, vitamin E cannot be recommended as a MASH-targeted therapy (**LoE 2, weak recommendation, strong consensus**).

Statement

- For individuals with MASLD undergoing therapy with resmetirom, data on sustainability of histological benefits, individual prediction of response, liver-related outcomes and long-term safety are not currently available (**LoE 5, strong consensus**).

In adults with MASH, is there sufficient evidence to recommend prescription of existing glucose-lowering drugs to reduce histologically/non-invasively assessed liver damage/fibrosis and liver-related outcomes compared to no pharmacological intervention?

Recommendations

- In the absence of a formal demonstration of histological improvement in large, well conducted, Phase III trials, glucagon-like peptide 1 receptor agonists (GLP1RA) can-

not currently be recommended as MASH-targeted therapies (**LoE 5, strong recommendation, strong consensus**).

- GLP1RAs are safe to use in MASH (including compensated cirrhosis) and should be used for their respective indications, namely type 2 diabetes and obesity, as their use improves cardiometabolic outcomes (**LoE 2, strong recommendation, strong consensus**).
- Where available, pioglitazone is safe to use in adults with non-cirrhotic MASH but given the lack of robust demonstration of histological efficacy on steatohepatitis and liver fibrosis in large Phase III trials, pioglitazone cannot be recommended as a MASH-targeted therapy (**LoE 2, weak recommendation, consensus**).
- There is insufficient evidence to recommend the use of sodium–glucose cotransporter-2 (SGLT2) inhibitors or metformin as MASH-targeted therapies; however, they are safe to use in MASLD and should be used for their respective indications, namely type 2 diabetes, heart failure and chronic kidney disease (**LoE 3, strong recommendation, strong consensus**).

Statements

- In case of substantial weight loss induced by GLP1RAs, a hepatic histological benefit could be expected, although this has not been extensively documented so far (**LoE 2, strong consensus**).
- There is insufficient evidence to support using any other glucose-lowering drug class as MASH-targeted therapies (**LoE 5, strong consensus**).

Figure 4 summarises the recommended choice of pharmacological treatment options in individuals with MASH, depending on comorbidities and stage of disease.

In adults with MASH, is there sufficient evidence to recommend prescription of existing weight-loss agents to reduce histologically/non-invasively assessed liver damage/fibrosis and liver-related outcomes compared to no pharmacological intervention?

Recommendation

- Non-incretin-based weight-loss agents are not recommended as MASH-targeted therapies (**LoE 5, strong recommendation, strong consensus**).

Treatment of MASLD: surgical and endoscopic therapy

In adults with MASLD and obesity, are bariatric/metabolic surgery procedures or endoscopic weight-loss interventions effective to reduce histologically/non-invasively assessed liver damage and liver-related outcomes compared with no intervention?

Recommendations

- In adults with non-cirrhotic MASLD who have an approved indication, bariatric surgery should be considered, because it can induce long-term beneficial effects on the liver and is associated with remission of type 2 diabetes and improvement of cardiometabolic risk factors (LoE 3, strong recommendation, strong consensus).
- In adults with MASLD-related compensated advanced chronic liver disease/compensated cirrhosis who have an approved indication, bariatric surgery can be considered but careful evaluation (indication, type of surgery, presence of clinically significant portal hypertension) by a multidisciplinary team with experience in bariatric surgery in this particular population is required (LoE 4, weak recommendation, strong consensus).
- Metabolic/bariatric endoscopic procedures require further validation as MASH-targeted therapy and cannot currently be recommended (LoE 4, weak recommendation, strong consensus).

End-stage liver disease and liver transplantation

In adults with MASH-related cirrhosis, should dietary and lifestyle recommendations be adapted to the severity of liver disease, nutritional status and sarcopenia?

Recommendations

- In adults with MASH cirrhosis, it is recommended that dietary and lifestyle recommendations be adapted to the severity of liver disease, nutritional status and the presence of sarcopenia/sarcopenic obesity (LoE 2, strong recommendation, strong consensus).
- In adults with sarcopenia, sarcopenic obesity or decompensated cirrhosis, it is recommended that a high-protein diet is provided, as well as a late-evening snack (LoE 2, strong recommendation, consensus).
- Moderate weight reduction can be suggested in adults with compensated cirrhosis and obesity, with an emphasis on high protein intake and physical activity to maintain muscle mass and reduce the risk of sarcopenia (LoE 3, weak recommendation, strong consensus).

The approach of the majority of nutritional interventions in cirrhosis is to supply at least 35 kcal/kg of body weight/day, with a daily recommended protein intake of 1.2–1.5 g/kg of body weight/day, and recommended strategies are summarised in ESM Table 8.

In adults with MASH-related cirrhosis, how should pharmacologic interventions for diabetes and lipid control or cardiovascular prevention be adapted to the severity of the liver condition?

Recommendations

- Metformin can be used in adults with compensated cirrhosis and preserved renal function but should not be used in adults




Fig. 4 Treatment recommendations beyond lifestyle modification in MASLD/MASH. The recommended choice of pharmacological treatment options in individuals with MASLD/MASH is dependent on comorbidities and stage of disease. T2D, type 2 diabetes

with decompensated cirrhosis, especially when there is concomitant renal impairment, because of the risk of lactic acidosis (**LoE 3, strong recommendation, strong consensus**).

- Sulfonyleureas should be avoided in adults with hepatic decompensation because of the risk of hypoglycaemia (**LoE 4, weak recommendation, strong consensus**).
- GLP-1 receptor agonists can be used in adults with Child–Pugh class A cirrhosis, according to its indication (**LoE 2, weak recommendation, strong consensus**).
- SGLT2 inhibitors can be used in adults with Child–Pugh class A and B cirrhosis (**LoE 4, weak recommendation, consensus**).
- Statins can be used in adults with chronic liver disease, including those with compensated cirrhosis; they should be used in adults according to cardiovascular risk guidelines to reduce cardiovascular events (**LoE 1, strong recommendation, strong consensus**).

In adults with MASLD, can non-invasive scores, serum markers, liver stiffness measurements and/or imaging replace hepatic venous pressure gradient (HVPG) and endoscopy in identifying individuals with clinically significant portal hypertension and varices requiring treatment, respectively?

Recommendations

- Liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) ≤ 15 kPa plus platelet count $\geq 150 \times 10^9/l$ may be used to rule out clinically significant portal hypertension (CSPH) in adults with MASLD (**LoE 3, weak recommendation, strong consensus**).
- If CSPH is present, non-selective beta-blockers may be started unless contraindicated (**LoE 3, weak recommendation, strong consensus**).
- In adults with compensated advanced chronic liver disease but LSM ≥ 20 kPa and/or platelet count $< 150 \times 10^9/l$, an upper gastrointestinal endoscopy should be performed to screen for varices unless they already fulfil the criteria to initiate non-selective beta-blockers (**LoE 3, strong recommendation, strong consensus**).

Statement

- The threshold of LSM ≥ 25 kPa to rule in CSPH is only applicable to non-obese (BMI < 30 kg/m²) adults with MASLD; while obesity can confound LSM, current evidence is insufficient to suggest the optimal non-invasive test to rule in CSPH in adults with MASLD and obesity (**LoE 3, strong consensus**).

In adults with MASLD who are candidates for liver transplantation, should the evaluation of (cardiometabolic)

comorbidities in the pre- and post-transplant phase be different from that of individuals with liver disease of other aetiologies?

Statement

- Adults with MASLD are at increased risk of major cardiovascular events in the pre-, peri- and post-transplant phase (**LoE 2, strong consensus**).

Recommendations


- Adults with MASLD who are candidates for liver transplantation should be evaluated by a multidisciplinary team for cardiovascular and metabolic comorbidities to mitigate the risk of major cardiovascular events in the pre-, peri- and post-transplant phase (**LoE 3, strong recommendation, strong consensus**).
- A comprehensive screening for comorbidities in adults with MASLD before liver transplantation (ESM Table 9), including a stepwise and risk-adjusted cardiac work-up algorithm (Fig. 5), may help to optimise management of adults with MASLD before, during and after liver transplantation (**LoE 5, weak recommendation, strong consensus**).

In potential liver transplant recipients with MASH and severe obesity, do pharmacologic treatments, endoscopic interventions and bariatric surgery for weight loss improve outcomes before and after transplantation?

Recommendations

- Adults with obesity and end-stage MASLD listed for liver transplantation should undergo therapeutic interventions aimed at weight reduction without worsening sarcopenia as this will improve peri-operative outcomes (**LoE 3, strong recommendation, strong consensus**).
- Implementation of dietary modification and supervised physical exercise should be the first line management approach with the objective of reducing BMI < 40 kg/m² and ideally < 35 kg/m² (**LoE 1, strong recommendation, strong consensus**).
- In adults with end-stage MASLD listed for liver transplantation, pharmacological weight-loss strategies may be considered after careful risk–benefit assessment (e.g. presence of sarcopenia, liver function impairment) (**LoE 4, weak recommendation, consensus**).
- In adults with compensated cirrhosis and without clinically significant portal hypertension, sleeve gastrectomy prior to liver transplantation may be considered as an alternative option to dietary or pharmacological weight loss (**LoE 3, open recommendation, strong consensus**).
- In case of decompensated cirrhosis, bariatric surgery is contraindicated and needs to be discussed in the context

Fig. 5 Cardiovascular work-up algorithm in the evaluation of individuals with MASLD before liver transplantation. Adults with MASLD who are candidates for liver transplantation should be evaluated by a multi-disciplinary team using a step-wise and risk-adjusted cardiac work-up algorithm to mitigate the risk of major cardiovascular events in the pre-, peri- and post-transplant phase (modified from [6, 7]). CCTA, coronary computed tomography angiography; CV, cardiovascular; DSE, dobutamine stress echocardiography; ECG, electrocardiogram; LT, liver transplantation; TTE, transthoracic echocardiography. *Indicates suboptimal sensitivity in high-risk populations



of considering liver transplantation (**LoE 4, open recommendation, strong consensus**).

Statement

- Weight loss and optimised treatment of comorbidities before transplantation may confer a benefit in terms of cardiovascular morbidity, as well as long-term survival and reduced recurrence of severe MASLD after liver transplantation (**LoE 3, strong consensus**).

In adults who received liver transplantation due to MASLD-related end-stage liver disease, can non-pharmacologic or pharmacologic measures reduce the risk of MASLD recurrence and improve long-term outcomes compared with no intervention?

Statements

- In adults transplanted for MASLD-related end-stage liver disease, there is a high risk of recurrence of MASLD after liver transplantation, especially in adults with several metabolic risk factors (**LoE 3, strong consensus**).
- Adults transplanted for MASLD-related end-stage liver disease are also at risk of cardiovascular events and kid-

ney disease which can negatively impact long-term survival (**LoE 2, strong consensus**).

- No specific issues related to MASLD are known to alter choice of medication or target values; the risk of recurrence of severe, fibrotic steatohepatitis reinforces the need to obtain optimal control of cardiometabolic risk factors (**LoE 5, strong consensus**).
- The benefit of controlling weight and obesity-related comorbidities on recurrence of MASLD post-liver transplant and on progression to advanced fibrosis is expected but needs to be demonstrated in dedicated trials (**LoE 5, strong consensus**).

Recommendations

- In adults transplanted for MASLD-related end-stage liver disease, therapeutic interventions to control obesity and related cardiometabolic complications are recommended (**LoE 3, strong recommendation, strong consensus**).
- After liver transplantation, standard non-pharmacological dietary and lifestyle interventions should be universally implemented; pharmacological management of hypertension, type 2 diabetes and lipid disorders should be implemented according to general clinical guidelines (**LoE 3, strong recommendation, strong consensus**).

Box 1. Key research agenda in MASLD (selected topics).**General management, natural history, prevention and screening**

- To develop widely implementable, efficient and cost-effective point of care diagnostics for case-finding; to define referral pathways for individuals with cardiometabolic risk factors in different national healthcare contexts.
- To understand individual susceptibility and determinants of fibrosis progression, course of cirrhosis and HCC occurrence in individuals with MASLD.
- To better describe the natural history of the MetALD segment of the SLD population and to develop reliable and quantitative biomarkers of alcohol consumption; to examine the relationship between metabolic dysfunction and amount of alcohol consumed on the progression of liver injury.
- To develop and implement national policies increasing awareness of SLD and prevention of MASLD in individuals of all ages including children and adolescents.

Use of non-invasive tests (NITs) in MASLD

- To qualify the most performant biomarkers for different contexts of use (diagnostic, monitoring, prognostic and treatment response) in individuals with MASLD.
- To determine, in the context of pharmacological therapy, if improvement in histological surrogates translates into clinical benefit; if changes in NITs mirror histological changes; and if future trials can use NITs as surrogates of treatment response.
- To determine personalised, risk-based HCC surveillance strategies in both cirrhotic and non-cirrhotic MASLD and MetALD individuals.
- To understand how AI-assisted diagnostics, including digital pathology, can improve risk stratification, determine treatment response and facilitate the conduct of therapeutic trials.
- To evaluate the application of Baveno VII criteria of clinically significant portal hypertension and the role of spleen stiffness measurement in individuals with MASLD.

Treatment for MASLD and comorbidities

- To improve on personalised lifestyle and dietary approaches for weight reduction, maintenance of weight loss and the identification of individuals most likely to benefit from non-pharmacological interventions alone.
- To identify early predictors of non-response to pharmacological intervention and to define clear stopping rules for MASH-targeted pharmacotherapy in non-responders.
- To evaluate the impact of controlling metabolic comorbidities on the hepatic disease course in MASLD.
- To determine weight loss-independent mechanisms of MASLD improvement for incretin-based, weight loss-based or glucose-lowering treatments.
- To determine whether improvement in steatotic liver injury will have a beneficial effect on metabolic dysfunction and control of comorbidities in MASLD.
- To prospectively assess the potential additive or synergistic effects of combining drugs intended to treat MASH and/or cardiometabolic comorbidities.
- To develop effective pharmacological treatments for individuals with MASH-related cirrhosis.

- GLP1 receptor agonists may be considered to control weight and obesity-related comorbidities, although specific trials in transplant recipients are needed (**LoE 5, weak recommendation, strong consensus**).

Future directions

Despite the enormous advances in the field, many important areas on the management of MASLD require further evidence to refine our clinical practice. Some of these areas, where further research is pressingly needed, are listed in Box 1.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00125-024-06196-3>.

Acknowledgements Clinical Practice Guideline Panel: Chair: Frank Tacke¹; Assistant to Chair: Paul Horn¹; EASL panel members: Vincent Wai-Sun Wong², Vlad Ratziu³, Elisabetta Bugianesi⁴, Sven Francque⁵, Shira Zelber-Sagi^{6,7}; EASL Governing Board repre-

sentative: Luca Valenti^{8,9}; EASD co-chair: Michael Roden^{10,11,12}; EASD panel members: Fritz Schick¹³, Hannele Yki-Järvinen^{14,15}, Amalia Gastaldelli¹⁶; EASO co-chair: Roberto Vettor¹⁷; EASO panel members: Gema Frühbeck¹⁸, Dror Dicker¹⁹. (Affiliations: ¹Department of Hepatology and Gastroenterology, Charité – Universitätsmedizin Berlin, Berlin, Germany; ²Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China; ³Sorbonne Université, Institute of Cardiometabolism and Nutrition, Hospital Pitié Salpêtrière, Paris, France; ⁴Department of Medical Sciences, Division of Gastroenterology, University of Turin, Turin, Italy; ⁵Department of Gastroenterology and Hepatology, Antwerp University Hospital, Edegem, Belgium; ⁶School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel; ⁷Department of Gastroenterology Tel-Aviv Medical Center, Tel-Aviv, Israel; ⁸Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy; ⁹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ¹⁰Department of Endocrinology and Diabetology, Medical Faculty, Heinrich-Heine University and University Hospital, Düsseldorf, Germany; ¹¹Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany; ¹²German Center for Diabetes Research (DZD), Partner Düsseldorf, München-Neuherberg, Germany; ¹³Department of Radiology, University Hospital of Tübingen, Tübingen, Germany; ¹⁴Uni-

versity of Helsinki and Helsinki University Hospital, Department of Medicine, Helsinki, Finland; ¹⁵Minerva Foundation Institute for Medical Research, Helsinki, Finland; ¹⁶Institute of Clinical Physiology, National Research Council-CNR, Pisa, Italy; ¹⁷Department of Medicine-DIMED, Università degli Studi di Padova, Padua, Italy; ¹⁸Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, CIBEROBN, IdiSNA, Pamplona, Spain; ¹⁹Internal Medicine D & Obesity Clinic, Hasharon Hospital-Rabin Medical Center. Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel)

The authors would like to thank the members of the Delphi Panel of this Clinical Practice Guideline for their valuable contribution: Quentin Anstee, Marco Arrese, Heike Bantel, Giulia Besutti, Jérôme Boursier, Christopher Byrne, Ali Canbay, Cyrielle Caussy, Helena Cortez-Pinto, Mattias Ekstedt, Mirto Foletto, Jacob George, Liana Gheorghie, Isabel Graupera, Hannes Hagström, Kate Hallsworth, Onno Holleboom, Achim Kautz, Marko Korenjak, Karoline Lackner, Christos Lionis, Giulio Marchesini, Juris J. Meier, Juan M. Mendive, Luca Miele, Geltrude Mingrone, J. Bernadette Moore, Philip Newsome, George Papatheodoridis, Valerie Paradis, Gianluca Perseghin, Ralph Peterli, Salvatore Petta, Manuel Romero-Gomez, Jörn M. Schattenberg, Silvia Sookoian, Wendy Spearman, Norbert Stefan, Maja Thiele, Dina Tiniakos, Emmanouil Tsochatzis, Bernard Van Beers, José Willemse, Yusuf Yilmaz, and Volkan Yumuk. The authors would also like to thank the external reviewers, and the EASL, EASD and EASO Governing Boards for their valuable contribution to the review process.

Authors' relationships and activities Luca Valenti has disclosed speaking engagements with Viatrix, Novo Nordisk, and GSK; consulting roles with Novo Nordisk, Pfizer, Boehringer Ingelheim, Resalis, and MSD; and received unrestricted grant support from Gilead. Elisabetta Bugianesi serves as a consultant for Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Pfizer, Bristol-Myers Squibb, and MSD. Amalia Gastaldelli has acted as a consultant for Boehringer Ingelheim, Eli Lilly and Company, and Metadeq Diagnostics; participated in advisory boards for Boehringer Ingelheim, Merck Sharp & Dohme, Novo Nordisk, Metadeq Diagnostics, and Pfizer; and received speaker's honorarium or other fees from Eli Lilly and Company, Merck Sharp & Dohme, Novo Nordisk, and Pfizer. Frank Tacke's lab has received research funding from Gilead, AstraZeneca, and MSD (funding to the institution); he has received honoraria for consulting or lectures from AstraZeneca, Gilead, AbbVie, BMS, Boehringer, Intercept, Falk, Inventiva, MSD, GSK, Orphan, Merz, Pfizer, Alnylam, Novo Nordisk, Sanofi, and Novartis. Michael Roden has participated in consulting for and/or scientific advisory boards of BMS, Boehringer Ingelheim Pharma, Echosens, Eli Lilly, Madrigal, MSD, Novo Nordisk, as well as in clinical trials supported by Boehringer Ingelheim, Novo Nordisk, and Nutricia/Danone. Paul Horn received grants from Novo Nordisk (through the University of Birmingham) and MSD (through Charité - Universitätsmedizin Berlin); speaking fees from Orphan; and travel support from IPSEN. Hannele Yki-Järvinen declares no conflicts of interest regarding the present work. Shira Zelber-Sagi received travel support for attending a conference and honoraria for a lecture presentation in this conference by AbbVie, a one-time consulting fee by SIEMENS, and holds an unpaid leadership role as Chair-elect of the EASL public health committee. Vincent Wong has served as a consultant or advisory board member for AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Intercept, Inventiva, Novo Nordisk, Pfizer, Sagimet Biosciences, TARGET PharmaSolutions, and Visirra; a speaker for Abbott, AbbVie, Echosens, Gilead Sciences, Novo Nordisk, and Unilab; received a research grant from Gilead Sciences, and is a co-founder of Illuminatio Medical Technology. Gema Frühbeck received payment of honoraria for attendance to

Advisory Boards from Lilly, and Novo Nordisk as well as payment of honoraria for lectures as Member of the OPEN Spain Initiative. Sven Francque holds a senior clinical investigator fellowship from the Research Foundation Flanders (FWO) and has acted as consultant for Astellas, Falk Pharma, Genfit, Gilead Sciences, GlympsBio, Janssens Pharmaceutica, Inventiva, Merck Sharp & Dome, Pfizer, Roche. He has acted as consultant for Abbvie, Actelion, Aelin Therapeutics, AgomAb, Aligos Therapeutics, Allergan, Alnylam, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CSL Behring, Coherus, Echosens, Dr. Falk Pharma, Eisai, Enyo, Galapagos, Galmed, Genetech, Genfit, Genflow Biosciences, Gilead Sciences, Intercept, Inventiva, Janssens Pharmaceutica, PRO.MED. CS Praha, Julius Clinical, Madrigal, Medimmune, Merck Sharp & Dome, Mursla Bio, NGM Bio, Novartis, Novo Nordisk, Promethera, Roche, Siemens Healthineers, and lectured for for Abbvie, Allergan, Bayer, Eisai, Genfit, Gilead Sciences, Janssens Cilag, Intercept, Inventiva, Merck Sharp & Dome, Novo Nordisk, Promethera, Siemens. Dror Dicker received grants, personal fees, and nonfinancial support from NovoNordisk and Eli Lilly, and personal fees and non-financial support from Boehringer Ingelheim outside the submitted work. Vlad Ratziu serves as a consultant for Novo-Nordisk, Madrigal, Boehringer-Ingelheim, GSK, and 89 Bio; and has a grant to institution from MSD. Fritz Schick declares no conflict of interest pertaining to this article. Roberto Vettor has received honoraria from Novo Nordisk, Eli Lilly and AstraZeneca, and has served on advisory boards for Novo Nordisk and Eli Lilly.

Contribution statement Each panel member was responsible for drafting a specific section of the guidelines. The Panel Chair and Assistant to Chair were then responsible for compiling and extensively revising the full manuscript text, which was subsequently reviewed, revised and approved by all panel members.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Karlsen TH, Sheron N, Zelber-Sagi S et al (2022) The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. *Lancet* 399(10319):61–116. [https://doi.org/10.1016/S0140-6736\(21\)01701-3](https://doi.org/10.1016/S0140-6736(21)01701-3)
2. Rinella ME, Lazarus JV, Ratziu V et al (2023) A multi-society Delphi consensus statement on new fatty liver disease nomenclature. *J Hepatol* 79(6):1542–56. <https://doi.org/10.1016/j.jhep.2023.06.003>
3. European Association for the Study of the Liver (2016) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 64(6):1388–402. <https://doi.org/10.1016/j.jhep.2015.11.004>

4. Younossi ZM, Paik JM, Stepanova M, Ong J, Alqahtani S, Henry L (2024) Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. *J Hepatol*. <https://doi.org/10.1016/j.jhep.2024.01.014>
5. OCEBM Levels of Evidence Working Group. “The Oxford 2011 Levels of Evidence”. Oxford Centre for Evidence-Based Medicine. 2011. Available from: <https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebml-levels-of-evidence>. Accessed 27 Jan 2023
6. Tsochatzis EA, Watt KD, VanWagner LB, Verna EC, Berzigotti A (2023) Evaluation of recipients with significant comorbidity - Patients with cardiovascular disease. *J Hepatol* 78(6):1089–104. <https://doi.org/10.1016/j.jhep.2023.03.023>
7. Burra P, Becchetti C, Germani G (2020) NAFLD and liver transplantation: Disease burden, current management and future challenges. *JHEP Rep* 2(6):100192. <https://doi.org/10.1016/j.jhepr.2020.100192>
8. Karlas T, Petroff D, Sasso M et al (2017) Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. *J Hepatol* 66(5):1022–30. <https://doi.org/10.1016/j.jhep.2016.12.022>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**EASL–EASD–EASO Clinical Practice Guidelines on the
management of metabolic dysfunction-associated steatotic liver
disease (MASLD): Executive Summary**

European Association for the Study of the Liver, European Association for the Study
of Diabetes and European Association for the Study of Obesity

*Clinical Practice Guideline Panel: chair: Frank Tacke; Assistant to Chair: Paul Horn;
EASL panel members: Vincent Wai-Sun Wong, Vlad Ratziu, Elisabetta Bugianesi,
Sven Francque, Shira Zelber-Sagi; EASL Governing Board representative: Luca
Valenti; EASD co-chair: Michael Roden; EASD panel members: Fritz Schick,
Hannele Yki-Järvinen, Amalia Gastaldelli; EASO co-chair: Roberto Vettor; EASO
panel members: Gema Frühbeck, Dror Dicker

Corresponding author: European Association for the Study of Diabetes (EASD), email:
info@easd.org

Table of content:

ESM Table 1. Grades of recommendation	3
ESM Table 2. Level of Evidence based on the Oxford Centre for Evidence-based Medicine (adapted).	3
ESM Table 3. Cardiometabolic risk factors in the definition of MASLD (1).	3
ESM Table 4. SLD due to aetiologies other than MASLD, MetALD or ALD.	4
ESM Table 5. Tools to quantify alcohol consumption and identify alcohol use disorders	5
ESM Table 6. Factors associated with a higher risk of HCC occurrence in non-cirrhotic MASLD.	5
ESM Table 7. Proposed tools for HCC risk-stratification in MASLD-related cirrhosis.	6
ESM Table 8. Summary of protein, energy, and dietary pattern recommendations for adults with cirrhosis as indicated by medical associations' Practice Guidance/ Guidelines. In addition, individuals with cirrhosis must abstain from alcohol.	7
ESM Table 9. Screening and management for comorbidities in individuals with MASLD before liver transplantation. Modified from (2, 3).	8
References	9

ESM Table 1. Grades of recommendation.

Grade	Wording	Criteria
Strong	Must, shall, should, is recommended Shall not, should not, is not recommended	Evidence, consistency of studies, risk-benefit ratio, individual preferences, ethical obligations, feasibility
Weak or open	Can, may, is suggested May not, is not suggested	

ESM Table 2. Level of Evidence based on the Oxford Centre for Evidence-based Medicine (adapted).

Level	Criteria	Simple model for high, intermediate and low evidence
1	Systematic Reviews (SR) (with homogeneity) of randomised controlled trials (RCT)	Further research is unlikely to change our confidence in the estimate of benefit and risk.
2	Randomised controlled trials (RCT) or observational studies with dramatic effects; Systematic Reviews (SR) of lower quality studies (i.e. non-randomised, retrospective)	
3	Non-randomised controlled cohort/follow-up study/control arm of randomised trial (systematic review is generally better than an individual study)	Further research (if performed) is likely to have an impact on our confidence in the estimate of benefit and risk and may change the estimate.
4	Case-series, case-control, or historically controlled studies (systematic review is generally better than an individual study)	
5	Expert opinion (mechanism-based reasoning)	Any estimate of effect is uncertain.

*Level may be graded down based on study quality, imprecision, indirectness (study does not match questions), because of inconsistency between studies, or because the absolute effect size is very small; Level may be graded up if there is a large or very large effect size.

ESM Table 3. Cardiometabolic risk factors in the definition of MASLD (1).

Metabolic risk factor	Adult criteria
Overweight or obesity	Body mass index ≥25 kg/m ² (≥23 kg/m ² in people of Asian ethnicity)
	Waist circumference ≥94 cm in men and ≥80 cm in women (Europeans) ≥90 cm in men and ≥80 cm in women (South Asians and Chinese) ≥85 cm in men and ≥90 cm in women (Japanese)
Dysglycaemia or type 2 diabetes	<u>Prediabetes</u> : HbA _{1c} 39-47 mmol/mol (5.7-6.4%) or fasting plasma glucose 5.6-6.9 mmol/L (100-125 mg/dl) or 2-h plasma glucose during OGTT 7.8-11 mmol/L (140-199 mg/dl) <i>or</i> <u>Type 2 diabetes</u> : HbA _{1c} ≥48 mmol/mol (≥6.5%) or fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dl) or 2-h plasma glucose during OGTT ≥11.1 mmol/L (≥200 mg/dl) <i>or</i> <u>Treatment for type 2 diabetes</u>
Plasma triglycerides	≥1.7 mmol/L (≥150 mg/dl) <i>or</i> lipid-lowering treatment
HDL-cholesterol	≤1.0 mmol/L (≤39 mg/dl) in men and ≤1.3 mmol/L (≤50 mg/dl) in women <i>or</i> lipid-lowering treatment
Blood pressure	≥130/85 mmHg <i>or</i> treatment for hypertension

HbA_{1c}, glycated haemoglobin; HDL, high-density lipoprotein; OGTT, oral glucose tolerance test

ESM Table 4. SLD due to aetiologies other than MASLD, MetALD or ALD.

Condition	Clinical/lab/histological findings	Diagnostic criteria
Hepatitis C virus-associated steatotic liver (genotype 3)	Low triglycerides, HCV genotype 3	HCV antibody with reflex testing HCV RNA and HCV genotype
Drug-induced Liver Disease (DILI)	Mostly microvesicular SLD	Investigate for drug intake: <ul style="list-style-type: none"> • Corticosteroids • Tamoxifen • Amiodarone • Irinotecan • Methotrexate • Lomitapide • Valproate • 5-Fluorouracil Liver biopsy for confirmation
Hypobetalipoproteinaemia	Low triglycerides and cholesterol, fat malabsorption, vitamin A deficiency	ApoB level, genetic testing (<i>APOB</i> , <i>MTTP</i> , <i>PCSK-9</i> , targeted panel sequencing)
Lipodystrophy	Accumulation of fat in the visceral area and in the muscle (generically inherited or induced by HAART therapy)	CT scan or MRI, targeted panel sequencing for congenital lipodystrophies, MRI
LAL deficiency (Wolman disease, cholesteryl ester storage disease-CESD)	Elevated LDL-C and triglycerides, low HDL-C, hypersplenism, advanced fibrosis in young age, predominately microvesicular steatosis	Enzyme assay, genetic testing (LIPA)
Pregnancy associated	HELLP syndrome Acute onset	Elevated liver enzymes and low platelets, haemolysis, SLD at abdominal ultrasound
Wilson disease	Younger age, neuropsychiatric symptoms, low ceruloplasmin	24-h urine copper excretion; quantitative copper on liver biopsy, genetic testing (<i>ATP7B</i>)
Nutrient deficiency / malnutrition	Parenteral nutrition, bypass surgeries, bariatric surgery, anorexia	Nutrient levels
Celiac disease	Diarrhoea, iron deficiency, vitamins deficiency	Tissue transglutaminase IgA, duodenal biopsy
Endocrine diseases	Hypothyroidism, PCOS, growth hormone (GH) deficiency, panhypopituitarism (primary or secondary)	TSH, fT4, fT3, endocrine testing
Other inherited metabolic conditions	Early age and severe onset, absence of triggering factors, systemic involvement, positive history of advanced disease in first degree relatives	Targeted panel sequencing, whole exome sequencing (WES)

ALD, alcohol-related liver disease; ApoB, apolipoprotein B; fT3, free triiodothyronine; fT4, free thyroxine; HCV, hepatitis C virus; HAART, highly active antiretroviral therapy; HELLP, haemolysis, elevated liver enzymes and low platelets; LAL, lysosomal acid lipase; MASLD, metabolic dysfunction-associated steatotic liver disease; PCOS, polycystic ovary syndrome; SLD, steatotic liver disease; TSH, thyroid-stimulating hormone.

ESM Table 5. Tools to quantify alcohol consumption and identify alcohol use disorders.

Psychometric instruments	Biomarkers
<ul style="list-style-type: none"> • Medical history (including current and prior alcohol intake and drinking pattern) • Quantity frequency questionnaires and diaries (Timeline Followback) • Apps (e.g. Drinkaware) • AUDIT (Alcohol Use Disorders Inventory Test) questionnaire – 10 questions • AUDIT-C (shortened version, 3 questions) • SIAC (Systematic Inventory of Alcohol consumption, 3 questions) 	Indirect alcohol markers: <ul style="list-style-type: none"> • GGT, AST, AST>ALT, MCV, %CDT Direct alcohol markers: <ul style="list-style-type: none"> • Alcohol (EtOH) in breath and/or serum • Ethyl glucuronide (in urine or hair) • Phosphatidylethanol • Less established: ethyl sulfate, fatty acid ethyl esters

AST/ALT, aspartate/alanine aminotransferase; CDT, carbohydrate-deficient transferrin; GGT, gamma-glutamyltransferase; MCV, mean corpuscular volume.

ESM Table 6. Factors associated with a higher risk of HCC occurrence in non-cirrhotic MASLD.

Factor(s)
Presence and duration of T2D, obesity or both
Older age
Concurrent alcohol intake and/or smoking
Individuals with FIB-4 >3.25
Individuals with LSM >10 kPa and increasing change in LSM over time

ESM Table 7. Proposed tools for HCC risk-stratification in MASLD-related cirrhosis.

NITs	Formula/model variables/data	Study cohorts	Performance
HCC risk score	age + sex + platelet count + albumin + AST/ \sqrt ALT available at: www.hccrisk.com	7,068 individuals with MASLD-related cirrhosis (407 incident HCC) Mean FU: 3.7 years	Derivation cohort, C-index = 0.749 Validation cohort, C-index = 0.718
aMAP	$(0.06 \times \text{age (years)} + 0.89 \times \text{sex (M = 1; F = 0)} + 0.48 \times [(\log_{10} \text{ bilirubin } (\mu\text{mol/L}) \times 0.66 + \text{albumin (g/L)} \times -0.085)] - 0.01 \times \text{platelets } (\times 10^3/\text{mm}^3) + 7.4) / 14.77 \times 100$	Overall individuals, n = 17,374 NVH validation cohort, n = 720 Total: 1,389 individuals with MASLD Median FU: 4.61 years F3-F4, n = 243 (17.5%)	NHV cohort: Overall, C-index = 0.85 Cirrhosis, C-index = 0.61 Overall, C-index = 0.887 F3-F4, C-index = 0.754
GALAD	$-10.08 + 0.09 \times \text{age (years)} + 1.67 \times \text{gender (M = 1, F = 0)} + 2.34 \times \log_{10} \text{ AFP (ng/ml)} + 0.04 \times \text{AFP-L3 } (\%) + 1.33 \times \log_{10} \text{ DCP (ng/ml)}$	389 individuals with MASH (28 incident HCC) Median FU: 167 months Cirrhosis, n = 77 (19.6%)	Higher GALAD score in individuals who developed HCC vs. individuals HCC-free as early as 1.5 years before HCC diagnosis
HEDS study	Risk factor associated to HCC development in individuals with cirrhosis: Male gender (OR = 2.47; 95% CI 1.54–4.07; $p < 0.001$) Years with cirrhosis (OR = 1.06; 95% CI 1.02–1.1; $p = 0.004$), Family h/o of liver cancer (OR = 2.69; 95% CI 1.11– 5.86; $p = 0.02$) Age (OR = 1.17; 95% CI 1.03–1.33; $p = 0.02$) Obesity (OR = 1.7; 95% CI, 1.08–2.73; $p = 0.02$) AST (OR = 1.54; 95% CI 0.97–2.42; $p = 0.06$) AFP (OR = 1.32; 95% CI 0.97–1.77; $p = 0.07$) Albumin (OR = 0.7; 95% CI 0.46–1.07; $p = 0.10$)	Total: 1,325 individuals with cirrhosis (95 incident HCC) Median FU: 2.2 years MASLD, n = 327 (24.9%); 19 incident HCC	Performance of the multivariate set of risk factors: C-index = 0.73
THRI	age + etiology + gender + platelets Age: <45 years = 0 points; 45–60 years, 50 points; >60 years, 100 points Etiology: autoimmune/HCV SVR, 0 points; other, 36 points; MASLD, 54 points; HCV/HBV, 97 points Gender: Female = 0 points; Male = 80 points Platelets: >200 = 0 points; 140–200 = 20 points; 80–130 = 70 points; <80 = 89 points Total: 0–366 points	Derivation cohort: 2,079 individuals with cirrhosis MASLD, n = 111 (5.3%) Total: 2,491 individuals with cirrhosis MASLD, n = 1,182 (48%)	10-year HCC incidence: low-risk (<120) = 3%; medium-risk (120–240) = 10% high-risk (>240) = 32% C-index = 0.69
LiverRisk score	Linear regression model using age (years), blood glucose, cholesterol, AST, ALT, GGT and platelets Available at: https://www.liverriskscore.com	Derivation cohort: 14,726 participants without known liver disease from the general population undergoing transient elastography for assessment of liver fibrosis. Two external validation cohorts: 4,370 and 3,999 individuals	8-year risk of HCC in the high- risk group = 4.4% 8-year risk of HCC development in the two lower risk groups \leq 0.1%

AFP, alpha-fetoprotein; DCP, Des- γ -carboxy prothrombin; FU, follow-up; OR, odds ratio.

ESM Table 8. Summary of protein, energy, and dietary pattern recommendations for adults with cirrhosis as indicated by medical associations' Practice Guidance/ Guidelines. In addition, individuals with cirrhosis must abstain from alcohol.

Society/ Association	EASL 2019		ESPEN 2019 and joint ESPEN/UEG guideline 2023		AASLD 2021	
	Mixed BMIs	Obese BMI >30 kg/m ²)	Mixed BMIs	Obese (BMI >30 kg/m ²)	Non-obese	Obese (non- hospitalised, clinically stable)
Daily energy	35 kcal/kg actual BW (in nonobese individuals)	>5–10% WR, moderately hypocaloric diet (-500–800 kcal/d)	30-35 kcal/kg only for DC. Regular energy requirements in CC	WR. No need for increased energy intake	≥35 kcal/kg body weight/day	25-35 kcal/kg/day for individuals with BMI 30- 40 kg/m ² , and 20-25 kcal/kg/day for individuals with BMI ≥40 kg/m ² . WR if medically required, under the supervision of a multidisciplinary team. Caution applied to prescribing weight loss in decompensated cirrhosis.
Daily protein	1.2–1.5 g/kg actual BW	>1.5 g/ kg IBW	1.2 g/kg (for non- malnourished individuals with CC) to 1.5 g/kg (to malnourished and/or sarcopenic cirrhosis)	Individuals with overweight or obesity and compensated cirrhosis: 1.2 g/kg ABW/d. Individuals with overweight or obesity and compensated cirrhosis undergoing weight-loss programs: 1.2–1.5 g/kg ABW/d. Individuals with overweight or obesity and compensated cirrhosis and malnutrition or sarcopenia: 1.5 g/kg ABW/d.	1.2-1.5 g/kg IBW. For individuals with cirrhosis who are critically ill, a target of 1.2- 2.0 g/kg IBW	Intake of target protein (1.2-1.5 g/kg/day) and physical activity are required to reduce the loss of muscle contractile function and muscle mass that can occur with weight loss.
Meal patterns	Split food intake into 3 main meals and 3 snacks		Three to five meals a day and a late evening snack		Maximum interval of 3-4 hours between nutritional intake while awake. To minimise nocturnal fasting time, an early breakfast and/or late-evening snack recommended	
Dietary protein source in case of HE	Individuals may tolerate animal protein (meat) less well than vegetable protein (beans, peas etc.) and dairy proteins		In individuals who are protein "intolerant", vegetable proteins should be used		A diverse range of protein sources, including vegetable and dairy products, should be encouraged.	

ABW, adjusted body weight; BMI, body mass index; CC, compensated cirrhosis; DC, decompensated cirrhosis; HE, hepatic encephalopathy; IBW, ideal body weight; WR, weight reduction.

ABW = reference body weight (in which BMI = 25) + 0.33*(actual body weight - reference body weight).

†In a case of fluid retention, body weight should be corrected by evaluating the individual's dry weight.

ESM Table 9. Screening and management for comorbidities in individuals with MASLD before liver transplantation. Modified from (2, 3).

Condition	Recommendation
Type 2 diabetes	<ul style="list-style-type: none"> • Screen for impaired fasting glucose (IFG) or glucose tolerance (IGT) and/or T2D (OGTT, HbA_{1c}) • Achieve good glycaemic control before LT • Preferentially use weight-lowering (e.g. SGLT2 inhibitors, GLP1RA) or weight-neutral (e.g. metformin) glucose lowering medication, considering risk of other diabetes complications, if liver and/or renal function allow this
Nutrition	<ul style="list-style-type: none"> • Assess nutritional status before LT • Assess alcohol consumption • Healthy diet, physical exercise and lifestyle modification (including weight reduction in individuals with obesity) represent pillars in pre-LT management
Cardiovascular	<ul style="list-style-type: none"> • Pre-LT cardiovascular risk stratification is mandatory • Risk-adapted algorithm of cardiac work-up should be followed (see Fig. 5) • LT candidates with cardiovascular risk should be managed with goal-directed medical management (e.g., statins, anti-platelet agents, beta blockers, RAAS blockers), based on the stage of cirrhosis and renal function
Kidney	<ul style="list-style-type: none"> • Kidney function should be adequately monitored before LT • Comedications need to be adjusted (or replaced) dependent on kidney function
Malignancies	<ul style="list-style-type: none"> • Screening for pre-LT malignancies should follow the same protocols applied to individuals with non-MASLD related cirrhosis (including gastrointestinal and genital cancers)

GLP1RA, glucagon-like peptide-1 receptor agonist; HbA_{1c}, glycated haemoglobin; LT, liver transplantation; MASLD, metabolic dysfunction-associated steatotic liver disease; OGTT, oral glucose tolerance test; RAAS, renin-angiotensin-aldosterone system; SGLT2, sodium-glucose cotransporter-2.

References

1. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. *J Hepatol.* 2023;79(6):1542-56.
2. Tsochatzis EA, Watt KD, VanWagner LB, Verna EC, Berzigotti A. Evaluation of recipients with significant comorbidity - Patients with cardiovascular disease. *J Hepatol.* 2023;78(6):1089-104.
3. Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: Disease burden, current management and future challenges. *JHEP Rep.* 2020;2(6):100192.